CELYAD ONCOLOGY SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.335 EUR | +6.35% |
|
-1.33% | -14.10% |
| Apr. 04 | Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Feb. 09 | Celyad Oncology Seeks Termination of Reporting Obligations to US SEC | MT |
Presenter SpeechGeorges Rawadi (Executives)Thank you, everyone, for joining us today as we rep...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Celyad Oncology SA is a biotechnology company focused on the discovery and development of innovative technologies chimeric antigen receptor (CAR) T-cell therapies. The company is focusing on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property and support the development of next-generation CAR T candidates in solid tumors and hematological malignancies.
Calendar
2024-05-01
- Q1 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -14.10% | 14.82M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- CYAD Stock
- News Celyad Oncology SA
- Transcript : Celyad Oncology SA, H1 2023 Earnings Call, Sep 05, 2023
